Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
| Status: | Recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 60 |
| Updated: | 4/2/2016 |
| Start Date: | October 2000 |
| Contact: | Emily Hart |
| Email: | mpgroup@mssm.edu |
| Phone: | 212-241-0441 |
The Dopaminergic System in Schizotypal Personality Disorder: Pergolide for Cognitive Symptoms in Schizotypal Personality Disorder
Hypothesis: Schizotypal personality disorder patients will show cognitive improvements in 1)
working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the
AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis
by drug administration of 0.3 mg of oral pergolide interaction for performance on the
cognitive tasks, with the schizotypal personality disorder group demonstrating significantly
improved peformance compared to the other personality disorder group after pergolide
compared with placebo.
Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects
receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed
by pergolide for four weeks.
working memory 2) learning and memory 3) sustained attention 4) enhanced performance on the
AX-CPT, N-back and Eriksen during pergolide treatment. There will be a significant diagnosis
by drug administration of 0.3 mg of oral pergolide interaction for performance on the
cognitive tasks, with the schizotypal personality disorder group demonstrating significantly
improved peformance compared to the other personality disorder group after pergolide
compared with placebo.
Design: Randomized, double-blind, crossover study of pergolide vs. placebo. Half of subjects
receive pergolide for eight weeks; half of subjects receive placebo for four weeks followed
by pergolide for four weeks.
Inclusion Criteria: DSM-IV criteria for Schizotypal Personality Disorder (or meets full
criteria bar one) or another personality disorder and shows impairment on markers of
cognitive functioning. Medically healthy, not abusing drugs or alcohol, is at least two
weeks medication-free and does not have significant neurological disease.
Exclusion Criteria: DSM-IV or RDC criteria for Schizophrenia or any Schizophrenia-related
psychotic disorder or for Bipolar Disorder. Any other Axis I disorders must be transient
and preceded by the personality disorder diagnosis, which should be primarily responsible
for subject’s functional impairment.
We found this trial at
1
site
Mount Sinai School of Medicine Icahn School of Medicine at Mount Sinai is proud to...
Click here to add this to my saved trials
